Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 5, 2016, Pages 384-395

  Velkoska, Elena ^a   Patel, Sheila K ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

angiotensin converting enzyme 2 activation; cardiovascular disease; diminazene aceturate; hypertension; renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIMINAZENE ACETURATE; ANTITRYPANOSOMAL AGENT; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BRAIN ISCHEMIA; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; EYE DISEASE; HEART INFARCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DRUG EFFECTS; ENZYMOLOGY; HYPERTENSION; METABOLISM;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DIMINAZENE; ENZYME ACTIVATION; HUMANS; HYPERTENSION; PEPTIDYL-DIPEPTIDASE A; TRYPANOCIDAL AGENTS;

EID: 84976589730     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000254     Document Type: Review

References (54)

1. Dzau V. The cardiovascular continuum and renin-Angiotensin-Aldosterone system blockade. J Hypertens Suppl 2005; 23: S9-S17
2. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-Angiotensin system. Trends Endocrinol Metab 2004; 15: 166-169
3. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9
4. Lew RA, Warner FJ, Hanchapola I, Smith AI. Characterization of angiotensin converting enzyme-2 (ACE2) in human urine. Int J Pept Res Ther 2006; 12: 283-289
5. Lew RA, Warner FJ, Hanchapola I, et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93: 685-693
6. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-579
7. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100: 8258-8263
8. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-375
9. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828
10. Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 2006; 27: 12-19
11. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011; 96: 287-294
12. Tikellis C, Pickering R, Tsorotes D, et al. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci (Lond) 2012; 123: 519-529
13. Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 2014; 66C: 167-176
14. Burrell LM, Burchill L, Dean RG, et al. Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol 2012; 97: 477-485
15. Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55: 90-98
16. Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122: 717-728
17. Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013; 52: 783-792
18. Shenoy V, Kwon KC, Rathinasabapathy A, et al.Oral delivery of Angiotensinconverting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension Hypertension 2014; 64: 1248-1259
19. Shil PK, Kwon KC, Zhu P, et al. Oral delivery of ACE2/Ang-(1-7) bioencapsulated in plant cells protects against experimental uveitis and autoimmune uveoretinitis. Mol Ther 2014; 22: 2069-2082
20. Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51: 1312-1317
21. Kulemina LV, Ostrov DA. Prediction of off-Target effects on angiotensinconverting enzyme 2. J Biomol Screen 2011; 16: 878-885
22. Abaru DE, Liwo DA, Isakina D, Okori EE. Retrospective long-Term study of effects of berenil by follow-up of patients treated since 1965. Tropenmed Parasitol 1984; 35: 148-150
23. da Silva Oliveira GL, de Freitas RM. Diminazene aceturate-An antiparasitic drug of antiquity: advances in pharmacology and therapeutics. Pharmacol Res 2015; 102: 138-157
24. Kuriakose S, Uzonna JE. Diminazene aceturate (Berenil), a new use for an old compound?. Int Immunopharmacol 2014; 21: 342-345
25. Peregrine AS, Mamman M. Pharmacology of diminazene: a review. Acta Trop 1993; 54: 185-203
26. Joubert KE, Kettner F, Lobetti RG, Miller DM. The effects of diminazene aceturate on systemic blood pressure in clinically healthy adult dogs. J S Afr Vet Assoc 2003; 74: 69-71
27. Adejumobi O, Abiola J, Adediran D, et al. Comparative effects of intramuscular and intravenous administration of diminazene aceturate on blood pressure and lead-II electrocardiogram of dogs. FASEB J 2015; 29: 980-981
28. Gjymishka A, Kulemina LV, Shenoy V, et al. Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug. FASEB J 2010; 24: 1032-1033
29. De Maria ML, Araujo LD, Fraga-Silva RA, et al. Antihypertensive effects of diminazene aceturate, an angiotensin-converting enzyme 2 activator, in rats. Protein Pept Lett 2016; 23: 9-16
30. Shenoy V, Gjymishka A, Yagna J, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med 2013; 187: 648-657
31. Rigatto K, Casali KR, Shenoy V, et al. Diminazene aceturate improves autonomic modulation in pulmonary arterial hypertension. Eur J Pharmacol 2013; 713: 89-93
32. Velkoska E, Patel SK, Griggs K, et al. Short-Term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. PLoS One 2015; 10: e0118758
33. Malek M, Nematbakhsh M. The preventive effects of diminazene aceturate in renal ischemia/reperfusion injury in male and female rats. Adv Prev Med 2014; 2014: 740647
34. Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin (1-7) in endothelin-1 induced ischemic stroke. Exp Physiol 2011; 96: 1084-1096
35. Bennion DM, Haltigan EA, Irwin AJ, et al. Activation of the neuroprotective angiotensin-converting enzyme 2 in rat ischemic stroke. Hypertension 2015; 66: 141-148
36. Qi Y, Zhang J, Cole-Jeffrey CT, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 2013; 62: 746-752
37. Fraga-Silva RA, Montecucco F, Costa-Fraga FP, et al. Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice. Vascul Pharmacol 2015; 74: 103-113
38. Fraga-Silva RA, Costa-Fraga FP, Montecucco F, et al. Diminazene protects corpus cavernosum against hypercholesterolemia-induced injury. J Sex Med 2015; 12: 289-302
39. Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2014; 34: 2617-2623
40. Coutinho DC, Monnerat-Cahli G, Ferreira AJ, Medei E. Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats. Europace 2014; 16: 1689-1696
41. Zhang Y, Liu J, Luo J, et al. Upregulation of angiotensin(1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid Redox Signal 2015; 23: 880-892
42. Foureaux G, Nogueira JC, Nogueira BS, et al. Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci 2013; 54: 4296-4306
43. Foureaux G, Franca JR, Nogueira JC, et al. Ocular inserts for sustained release of the angiotensin-converting enzyme 2 activator, diminazene aceturate, to treat glaucoma in rats. PLoS One 2015; 10: e0133149
44. Qiu Y, Shil PK, Zhu P, et al. Angiotensin-converting enzyme 2 (ACE2) activator DIZE ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci 2014; 55: 3809-3818
45. Zheng C, Lei C, Chen Z, et al. Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis. Mol Vis 2015; 21: 403-411
46. de Macedo SM, Guimarares TA, Andrade JM, et al. Angiotensin converting enzyme 2 activator (DIZE) modulates metabolic profiles in mice, decreasing lipogenesis. Protein Pept Lett 2015; 22: 332-340
47. Wang L, de Kloet AD, Pati D, et al. Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors. Neuropharmacology 2016; 105: 114-123
48. Dean RG, Burrell LM. ACE2 and diabetic complications. Curr Pharm Design 2007; 13: 2730-2735
49. Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015; 131: 97-106
50. Murca TM, Moraes PL, Capuruco CA, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept 2012; 177: 107-115
51. Ferreira AJ, Foureaux DEFG, Nogueira JC, et al., Pharmaceutical compositions containing angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis activators for the treatment of ocular pathological conditions. Patent WO 2013110152 A1 BR2013/000029. 2013
52. Tao L, Qiu Y, Fu X, et al. Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kB pathways in human retinal pigment epithelium. J Neuroinflammation 2016; 13: 35
53. Haber PK, Ye M, Wysocki J, et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension 2014; 63: 774-782
54. Raffai G, Khang G, Vanhoutte PM. Angiotensin-(1-7) augments endotheliumdependent relaxations of porcine coronary arteries to bradykinin by inhibiting ACE1. J Cardiovasc Pharmacol 2014; 63: 453-460